Inflammatory breast cancer cells are constitutively adapted to hypoxia

Cell Cycle

Volumn 8, Issue 19, 2009, Pages 3091-3096

  Silvera, Deborah ^a   Schneider, Robert J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4E BP1; Breast cancer; eIF4G; Hypoxia; Inflammatory breast cancer; Internal ribosome entry site; Protein synthesis; Translational control; VEGF

Indexed keywords

CATENIN; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4F; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN KINASE B; RAPAMYCIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TUBERIN; UVOMORULIN; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL HYPOXIA; CELL SURVIVAL; GENE SILENCING; HUMAN; INFLAMMATORY BREAST CANCER; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; RNA TRANSLATION; TUMOR EMBOLISM;

EID: 70349914220     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.19.9637     Document Type: Review

References (22)

1. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004; 10:6789-6795 (Pubitemid 39383027)
2. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28:501-512 (Pubitemid 350030573)
3. Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 2003; 88:718-725 (Pubitemid 36411451)
4. Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 2006; 26:3955-3965 (Pubitemid 43726410)
5. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003; 8:141-148 (Pubitemid 36428280)
6. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8:425-437 (Pubitemid 351744964)
7. Gong Y. Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype. Semin Oncol 2008; 35:33-40.
8. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47. (Pubitemid 37328806)
9. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002; 21:3172-3180 (Pubitemid 34552242)
10. Koritzinsky M, Wouters BG. Hypoxia and regulation of messenger RNA translation. Methods Enzymol 2007; 435:247-273
11. Lo AC, Georgopoulos A, Kleer CG, Banerjee M, Omar S, Khaled H, et al. Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients. Breast 2009; 18:55-59
12. Lo AC, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, et al. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat 2008; 112:141-147
13. McCarthy NJ, Yang X, Linnoila IR, Merino MJ, Hewitt SM, Parr AL, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002; 8:3857-3862 (Pubitemid 35424780)
14. Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989; 64:1922-1927
15. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001; 61:445-451 (Pubitemid 32128594)
16. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009.
17. Van den Eynden GG, Van der Auwera I, Van Laere S, Colpaert CG, van Dam P, Merajver S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 2004; 85:13-22. (Pubitemid 38437979)
18. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10:7965-7971 (Pubitemid 39587537)
19. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000; 2:418-425 (Pubitemid 32044787)
20. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60:5832-5838
21. Vaupel P, Briest S, Hockel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/ therapeutic implications. Wien Med Wochenschr 2002; 152:334-342 (Pubitemid 34824207)
22. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8:851-864